Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
May 30 2009 - 9:00AM
PR Newswire (US)
COLLEGEVILLE, Pa., May 30 /PRNewswire-FirstCall/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE:WYE), has donated
$100,000 to The American Society of Clinical Oncology (ASCO) Cancer
Foundation to help support its efforts to advance cancer research,
provide patients with important health information and conduct
physician education programs. The donation was presented today
during the 45th Annual Meeting of the American Society of Clinical
Oncology in Orlando, Fla. "Wyeth is proud to support The ASCO
Cancer Foundation and its ongoing mission to improving the lives of
people with cancer. With this contribution, we hope to help the
Foundation in its important educational and research efforts to
reach more patients and their families, and to provide additional
resources to the researchers seeking new treatments to help better
manage cancer," said Mikael Dolsten, M.D., Ph.D., President,
Research and Development, Wyeth Pharmaceuticals. "We are honored to
receive this generous donation from Wyeth," said Dr. Joseph Bailes,
Chair, The ASCO Cancer Foundation. "As we celebrate our 10th
Anniversary this year, we are especially grateful to all the
organizations that have helped us achieve this important milestone.
This donation will help us continue to make a world of difference
in cancer care." The American Cancer Society projected that more
than 1.4 million people in the United States would be diagnosed
with cancer in 2008. While the overall incidence of cancer has
declined in the past several years, these statistics vary greatly
by type of cancer and stage at diagnosis. Wyeth Pharmaceuticals
researches, develops and markets therapies for the treatment of
cancer. The ASCO Cancer Foundation supports educational programs of
the highest quality in cancer care and prevention; facilitates the
dissemination of information about cancer and cancer treatment to
patients and their families; and, through its grant program,
supports, encourages and recognizes excellence in clinical research
in the field of oncology. About Wyeth Pharmaceuticals Wyeth
Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal
health, central nervous system, inflammation, transplantation,
hemophilia, oncology, vaccines and nutritional products. Wyeth is
one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals,
vaccines, biotechnology products, nutritionals and non-prescription
medicines that improve the quality of life for people worldwide.
The Company's major divisions include Wyeth Pharmaceuticals, Wyeth
Consumer Healthcare and Fort Dodge Animal Health. The statements in
this press release that are not historical facts are
forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, among others, risks related to our proposed
merger with Pfizer, including satisfaction of the conditions of the
proposed merger on the proposed timeframe or at all, contractual
restrictions on the conduct of our business included in the merger
agreement, and the potential for loss of key personnel, disruption
in key business activities or any impact on our relationships with
third parties as a result of the announcement of the proposed
merger; the inherent uncertainty of the timing and success of, and
expense associated with, research, development, regulatory approval
and commercialization of our products and pipeline products;
government cost-containment initiatives; restrictions on
third-party payments for our products; substantial competition in
our industry, including from branded and generic products; emerging
data on our products and pipeline products; the importance of
strong performance from our principal products and our anticipated
new product introductions; the highly regulated nature of our
business; product liability, intellectual property and other
litigation risks and environmental liabilities; the outcome of
government investigations; uncertainty regarding our intellectual
property rights and those of others; difficulties associated with,
and regulatory compliance with respect to, manufacturing of our
products; risks associated with our strategic relationships; global
economic conditions; interest and currency exchange rate
fluctuations and volatility in the credit and financial markets;
changes in generally accepted accounting principles; trade buying
patterns; the impact of legislation and regulatory compliance;
risks and uncertainties associated with global operations and
sales; and other risks and uncertainties, including those detailed
from time to time in our periodic reports filed with the Securities
and Exchange Commission, including our current reports on Form 8-K,
quarterly reports on Form 10-Q and annual report on Form 10-K,
particularly the discussion under the caption "Item 1A, Risk
Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2008, which was filed with the Securities and Exchange
Commission on February 27, 2009. The forward-looking statements in
this press release are qualified by these risk factors. We assume
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise. DATASOURCE: Wyeth Pharmaceuticals CONTACT: Media,
Danielle Halstrom, +1-215-280-3898 (onsite), or Douglas Petkus,
+1-973-660-5218; or Investors, Justin Victoria, +1-973-660-5340,
all of Wyeth Pharmaceuticals Web Site: http://www.wyeth.com/
Copyright
Wyeth (NYSE:WYE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Wyeth (NYSE:WYE)
Historical Stock Chart
From Jul 2023 to Jul 2024